Successful combination of anti-cd33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia-Reference-Cited by-同舟云学术

Successful combination of anti-cd33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia

Published:2003-03 Issue:6 Volume:120 Page:1093-1094
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Hänel Mathias,Thiede Christian,Helwig Anett,Prange-Krex Gabriele,Babatz Jana,Haack Michael,Kroschinsky Frank,Fetscher Sebastian,Ehninger Gerhard,Bornhäuser Martin

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2003.04208_4.x/fullpdf

Reference5 articles.

1. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects;McSweeney;Blood,2001

2. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing cell reactive antibodies?;Selenko;Journal of Clinical Immunology,2002

3. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse;Sievers;Journal of Clinical Oncology,2001

4. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers;Thiede;Leukemia,2001

5. Management of relapsed acute myeloid leukaemia;Webb;British Journal of Haematology,1999

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation;Medicine;2020-08-28

2. Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia;Clinical Cancer Research;2008-09-01

3. Monoclonal Antibodies for the Treatment of Acute Myeloid Leukemia;Current Pharmaceutical Biotechnology;2006-10-01

4. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT;European Journal of Haematology;2004-11-02